Microangiopathic antiphospholipid syndrome in obstetric practice - the risk of generalized thrombotic microangiopathy


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

A systematic analysis of the data available in the modern literature on the microangiopathic antiphospholipid syndrome (APS) and other variants of the development of thrombotic microangiopathy (TMAP), incl. HELLP-syndrome and preeclampsia, up to 20 weeks of gestation, options for management of such pregnancies and the risks of obstetric complications in patients with APS was performed. a description of 2 clinical cases of various microangiopathic APS in obstetric practice, complicated by the development of HELLP-syndrome up to 20 weeks of gestation, is presented. These cases not only demonstrate the possibility of HELLP-syndrome debut before the 20th week of pregnancy, but also the development of HELLP-syndrome with a normal SfltI/PLGF level, which seems to confirm the apartness of HELLP-syndrome from pre-eclampsia. In both cases, positivity for all three groups of main antiphospholipid antibodies was registered, which initially increased the risk of obstetric complications, despite the adequacy of treatment. The need to isolate a microangiopathic APS is confirmed by the danger of development of all cases of TMAP signs in APS patients: the risk of TMAP generalization up to the catastrophic APS is unreasonably high. Only the use of heparins (including low molecular weight heparins) in combination with acetylsalicylic acid can be considered as the “gold” standard for the management of such patients. Addition of hydroxychloroquine may improve the outcome of such pregnancies, which requires confirmation in large multicenter studies.

Full Text

Restricted Access

About the authors

T. V Kirsanova

FSBI "National Medical Research Center of Obstetrics, Gynecology and Perinatology N.A. Acad. V.I. Kulakov” of the Ministry of Health of the Russian Federation

Email: a_tatya@mail.ru
PhD in Medical Sciences, Senior Researcher at the Department of Reproductive Hematology and Clinical Hemostasiology

M. A Vinogradova

FSBI "National Medical Research Center of Obstetrics, Gynecology and Perinatology N.A. Acad. V.I. Kulakov” of the Ministry of Health of the Russian Federation

PhD in Medical Sciences, Hematologist, Head of the Department of Reproductive Hematology and Clinical Hemostasiology

A. I Kolyvanova

M.V. Lomonosov Moscow State University

Applicant of the Department of Internal Diseases, Faculty of Fundamental Medicine

References

  1. Viner M., Murakhovskaya I. A rare combination of thrombotic thrombocytopenic purpura and antiphospholipid syndrome. Blood Coagul. Fibrinolysis. 2017;28(5):411-415. doi: 10.1097/MBC.0000000000000608.
  2. Matsuda J., Sanaka T., Gohchi K., et al. Occurrence of thrombotic thrombocytopenic purpura in a systemic lupus erythematosus patient with antiphospholipid antibodies in association with a decreased activity of von Willebrandfactor-cleaving protease. Lupus. 2002;11(7):463-464.
  3. Asherson R.A., Pierangeli S.S., Cervera R. Is there a microangiopathic antiphospholipid syndrome?Ann. Rheum. Dis. 2007;66(4):429-432.
  4. Amoura Z, Costedoat-Chalumeau N., Veyradier A., et al. Thrombotic thrombocytopenic purpura with severe ADAMTS-13 deficiency in two patients with primary antiphospholipid syndrome. Arthr. Rheum. 2004;50(10): 3260-3264.
  5. Asherson R. New subsets of the antiphospholipid syndrome in 2006: PREAPS (probable APS) and microangiopathic antiphospholipid syndromes (MAPS).Autoimmun. Rev. 2006;6(2):76-80. Doi: 10.1016/ j.autrev.2006.06.008.
  6. Simatov R., La Sala J.M., Lo S.K., et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J. Clin. Invest. 1995;96(5):2211-2219.
  7. Holers V.M., Giradi G., Mo L., et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J. Exp. Med. 2002; 195(2):211-220.
  8. Zhou H., Woldberg A.S., Roubey R.A. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood. 2004;104(8):2353-2358.
  9. Hazra S., Waugh J., Bosio P. ’Pure’ pre-eclampsia before 20 weeks of gestation: A unique entity. BJOG. 2003;110:1034-1035.
  10. Bornstein E., Barnhard Y., Atkin R., et al. HELLP syndrome: a rare, early presentation at 17 weeks of gestation. Obstet. Gynecol. 2007;110(2):525-527. doi: 10.1097/01.AOG.0000268512.26170.ad.
  11. Sherer D.M., Dalloul M., Stimphil R., et al. Acute onset of severe hemolysis, elevated liver enzymes, and low platelet count syndrome in a patient with a partial hydatidiform mole at 17 weeks gestation. Am. J. Perinatol. 2006;23(3):163-166. doi: 10.1055/s-2006-934093.
  12. Stefos T., Plachouras N., Mari G., et al. A case of partial mole and atypical type I triploidy associated with severe HELLP syndrome at 18 weeks ’ gestation. Ultrasound Obstet. Gynecol. 2002;20(4):403^04.
  13. Haram K., Trovik J., Sandset P.M., et al. Severe syndrome of hemolysis, elevated liver enzymes and low platelets (HELLP) in the 18th week of pregnancy associated with the antiphospholipid-antibody syndrome. Acta Obstet. Gynecol. Scand. 2003;82(7):679-680.
  14. McMahon L.P., Smith J. The HELLP syndrome at 16 weeks gestation: possible association with the antiphospholipid syndrome. Aust N. Z. J. Obstet. Gynaecol 1997;37(3):313-314.
  15. Falkert A., Yildiz A., Seelbach-Goebel B. Partial mole with fetal triploidy as a cause for imminent HELLP-syndrome at 16 weeks of gestation. Arch. Gynecol. Obstet. 2009;279(3):423-425.
  16. Myer E., Hill J. First Trimester Hemolysis, Elevated Liver Enzymes, Low Platelets Syndrome in a Surrogate Pregnancy. AJP. Rep. 2015;5(2):212-214. doi: 10.1055/s-0035-1563389.
  17. Maya I.D. Hypertension and proteinuria in a 17-year-old at 19 weeks’ gestation. Am. J. Kidney Dis. 2008;51:155-159.
  18. Tanaka M., Tsujimoto Y., Goto K., et al. Preeclampsia before 20 weeks of gestation: a case report and review of the literature. CEN. Case Reports. 2015;4(1):55-60.
  19. Toshiyuki I., Tetsuji N., Motonobu N., et al. A case of “pure”preeclampsia with nephrotic syndrome before 15 weeks of gestation in a patient whose renal biopsy showed glomerular capillary endotheliosis. Am. J. Kidney Dis. 2006;48:495-01.
  20. Stillman I.E., Karumanchi S.A. The glomerular injury of preeclampsia. J. Am. Soc. Nephrol. 2007;18:2281-2284.
  21. Thomas W., Griffiths M., Nelson-Piercy C., et al. Clinical Pre-eclampsia before 20-week gestation: diagnosis, investigation and management. Kidney Journal. 2012;5(6):597-599.
  22. Eltayeb S., Gowri V, Othman S., et al. A stormy and rare presentation: Eclampsia at 18 weeks of gestation. Obstet. Med. 2014;7(1):43-44.
  23. Shi J., Yang Z., Chen L. Study on the heterogeneity of edema in severe preeclampsia. Zhonghua Yi Xue Za Zhi. 2014;94(17):1342-1345.
  24. Nakakita B., Mogami H., Kondoh E. Case of soluble fms-like tyrosine kinase 1 apheresis in severe pre-eclampsia developed at 15 weeks’ gestation. J. Obstet. Gynaecol. 2015;41(10):1661-1663. doi: 10.1111/jog.12760
  25. Asherson R.A., Cervera R. Catastrophic antiphospholipid syndrome. Curr. Opin. Hematol. 2000;7:325-329.
  26. Cervera R., Bucciarelli S., Plasin M.A., et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the «CAPS Registry». J. Autoimmun. 2009;32(3-4):240-245.
  27. Asherson R.A. Multiorgan failure and antiphospholipid antibodies: the catastrophic antiphospholipid(Ashersons)syndrome. Immunobiol. 2005;210:727-733.
  28. Beucher G., Simonet T., Dreyfus M. Management of the HELLP syndrome. Gynecol. Obstet. Fertil. 2008;36(12):1175-1190.
  29. Haram K., Svendsen E., Abildgaard U. The HELLP syndrome: clinical issues and management. A Review. BMC. Pregnancy Childbirth. 2009;9:8.
  30. Pijnenborg R., Vercruysse L., Hanssens M., et al. Endovascular trophoblast and preeclampsia: A reassessment. Pregnancy Hypertens. 2011;1:66-71.
  31. Berry E.L., Iqbal S.N. HELLP-syndrome at 17 Weeks Gestation: A Rare and Catastrophic Phenomenon. J. Clin. Gynecol. Obstet. 2014;3(4):147-150.
  32. Hanouna G., Morel N., Le Thi Huong D., et al. Catastrophic antiphospholipid syndrome and pregnancy: An experience of 13 cases. Rheumatol. 2013;52(9):1635-1641.
  33. Appenzeller S., Souza F.H., Wagner Silva de Souza A., et al. HELLP-syndrome and its relationship with antiphospholipid syndrome and antiphospholipid antibodies. Semin. Arthr. Rheum. 2011;41(3):517-523.
  34. Ornstein M.H., Rand J.H. An association between refractory HELLP-syndrome and antiphospholipid antibodies during pregnancy: A report of 2 cases. J. Rheumatol. 1994;21:1360-1364.
  35. Wada Y., Sakamaki Y., Kobayashi D., et al. HELLP syndrome, multiple liver infarctions, and intrauterinefetal death in a patient with systemic lupus erythematosus and antiphospholipid syndrome. Int. Med. 2009;1(48):1555-1558.
  36. Кирсанова Т.В., Виноградова М.А., Федорова Т.А. Имитаторы тяжелой преэклампсии и HELLP-синдрома: различные виды тромботической микроангиопатии, ассоциированной с беременностью. Акушерство и гинекология. 2016;12:5-14.
  37. Le Thi Thuong D., Tieulie N., Costedoat N., et al. The HELLP ' syndrome in the antiphospholipid syndrome: retrospective study of 16 in 15 women. Ann. Rheum. Dis. 2005;64(2):273-278.
  38. Kitchens C.S. Thrombotic storm: when thrombosis begets thrombosis. Am. J. Med. 1998;104(4):381-385.
  39. Allen VM., Wilson R.D., Cheung A. Pregnancy outcomes after assisted reproduc tive technology. Genetics committee, reproductive endocrinology and infertility committee. J. Obstet. Gynaecol. Can. 2006;28(3):220-233. doi: 10.1016/S1701-2163(16)32112-0.
  40. Shanis L., Jessmon P., Sinaii N., et al. IVF and increased risk for preeclampsia revisited: a meta-analysis. Fertil. Steril 2011;96(3):181.
  41. Schutter J.M., Schuitemaker N.W., Steegers E.A., et al. Maternal death after oocyte donation at high maternal age: case report. Reprod. Health. 2008;30:5-12.
  42. Guballa N., Sammaritano L., Schwartzman S., et al. Ovulation induction and in vitro fertilization in systemic lupus erythematosus and antiphospholipid syndrome. Arthr. Rheum. 2000;43:550-556.
  43. Orquevaux P., Masseau A., Le Guern V. In vitro Fertilization in 37 Women with Systemic Lupus Erythematosus or Antiphospholipid Syndrome: A Series of 97 Procedures. J. Rheumatol. 2017;44(5):613-618. doi: 10.3899/jrheum160462.
  44. Chen X., Mo M.L., Huang C.Y. Association of serum autoantibodies with pregnancy outcome of patients undergoing first IVF/ICSI treatment: A prospective cohort study. J. Reprod Immunol. 2017;122:1^20. Doi: 10.1016/j. jri.2017.08.002.
  45. Reimand, K., Talja I., Metsküla K., et al. Autoantibody studies of female patients with reproductive failure. J. Reprod. Immunol. 2001;51:167-176.
  46. Cervera, R., Balasch, J. Bidirectional effects on autoimmunity and reproduction. Hum. Reprod. 2008;14:359-366.
  47. Gris J.C., Bouvier S., Molinari N., et al. Comparative incidence of a first thrombotic event in purely obstetric antiphospholipid syndrome with pregnancy loss: the NOH-APS observational study. Blood. 2012;119(11):2624-2632.
  48. Kim M.Y., Buyon J.P., Guerra M.M., et al. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am. J. Obstet. Gynecol. 2016;214(1):108.e1-108.e14. doi: 10.1016/j.ajog.2015.09.066.
  49. Van Hoorn M.E., Hague W.M., van Pampus B. Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset preeclampsia in women with antiphospholipid antibodies: the FRUIT-RCT. Eur. J. Obstet. Gynecol Reprod. Biol. 2016;197:168-173. Doi: 10.1016/ j.ejogrb.2015.12.011.
  50. Bates S.M., Greer I.A., Middeldorp S., et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2):e691S^736S.
  51. Chighizola С., Ubiali T., Meron P. Treatment of Thrombotic Antiphospholipid Syndrome: The Rationale of Current Management - An Insight into Future Approaches. J. Immunol. Res. 2015;1:1-20.
  52. Chighizola C.B., Gerosa M., Trespidi L. Update on the current recommendations and outcomes in pregnant women with antiphospholipid syndrome. Expert. Rev. Clin. Immunol 2014;10(11):1505-1517.
  53. Suryanarayan D., Garcia D. Anti-Phospholipid Antibodies and Pregnancy. Ask the Hematol. Compendium. 2014;11(4).
  54. Hansen E. H., Jessing P., Lindewald H., et al. Hydroxychloroquine sulphate in prevention of deep venous thrombosis following fracture of the hip, pelvis,or thoracolumbar spine. J. Bone Joint Surg. Am 1976; 58:1089-1093.
  55. Edwards M.H., Pierangeli S.S., Liu J.H., et al. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation. 1997;96:4380-4384.
  56. Espinola R.G., Pierangeli S.S., Gharavi A.E., et al. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb. Haemost. 2002;87:518-522.
  57. Sciascia S., Hunt B.J., Talavera-Garcia E., et al. The impact of hydroxychloroquine treatment on pregnancy outcome in women with antiphospholipid antibodies. Am. J. Obstet. Gynecol. 2016;214:273.e1-8.
  58. Sciascia S., Branch D.W., Levy R.A., et al. The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment. Thromb. Haemost. 2016;115:285-290. doi: 10.1160/TH15-06-0491.
  59. Mekinian A., Lazzaroni M.G., Kuzenko A., et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun. Rey. 2015;14:498-502.
  60. Andreoli L., Bertsias G.K., Agmon-Levin N., et al. EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann. Rheum. Dis. 2017;76:476^85. Doi: 10.1136/ annrheumdis-2016-209770.
  61. Schreiber K., Breen K., Cohen H. Hydroxychloroquine to Improve Pregnancy Outcome in Women with Antiphospholipid Antibodies (HYPATIA) Protocol: A Multinational Randomized Controlled Trial of Hydroxychloroquine versus Placebo in Addition to Standard Treatment in Pregnant Women with Antiphospholipid Syndrome or Antibodies. Semin. Thromb. Hemost. 2017;43(6):562-571. doi: 10.1055/s-0037-1603359.
  62. Kirsanova T., Vinogradova M., Kolyvanova A., et al. HELLP-syndrome-a link to aHUS: laboratory features of preeclampsia, HELLP-syndrome and pregnancu associated atypical hemolytic uremic syndrome. Nephrol. Dial. Transplant. 2017;32(3):524-525. Doi:https://doi.org/10.1093/ ndt/gfx167.MP266.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies